Copy
CANCER CLINICAL TRIALS NEWSLETTER
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

This is a global, multicenter, randomized, open-label, Phase 3 study for patients with progressive, advanced, kinase inhibitor naïve, RET-mutant medullary thyroid cancer. Patients randomized to Arm A will take selpercatinib twice daily, and patients in Arm B will take oral Cabozantinib or vandetanib once daily. The primary goal of this study is to examine treatment failure-free survival between the patients treated with selpercatinib vs those treated with Cabozantinib or vandetanib. (J2G-MC-JZJB, IRB 2019-1060)

Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!
New phone-based application available to all UC Cancer Center members and colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? Now, the UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all to use when recruiting patients into studies.

Application users are provided information on each of the Center’s recruiting studies to aid in screening and discussing study participation with patients. This includes study summaries, inclusion and exclusion criteria, other pertinent study information, and a streamlined way to contact the primary research coordinator for each study. IN ORDER TO START USING THIS APPLICATION, go to the website https://ctra.codehatcher.com on your phone and then add the application to your home screen. Your UC Cancer Center research team can also assist you. For further questions please reach out to Dr. Dylan Steen @ 908-208-6927, steendl@ucmail.uc.edu or Ginger Conway @859-992-5339, gingerconway8@gmail.com.
Study reveals potential new treatment for patients with melanoma

UC research has shown that radiation before immunotherapy may prolong lives of patients with melanoma that has spread to the brain. 
Click Here to Visit the UC Newsroom
State of the Science Summit: Ovarian Cancer
Thursday, April 23rd, 2020  | 5pm-9pm.
Renaissance Cincinnati Downtown Hotel
36 E 4th St. Cincinnati, OH 45202


Register online at OncLive.com/meetings/SOSS.  For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Multidisciplinary Management of Gastrointestinal Cancers 

Saturday, March 28th, 2020  | 7:30 a.m.–12:00 p.m.
The Manor House Banquet & Conference Center 7440 S. Mason-Montgomery Road
Mason, Ohio 45040

Keynote Speaker:
E. Gabriela Chiorean, MD
Professor of Medicine; Director of GI Oncology
University of Washington / Fred Hutchinson Cancer Research Center


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Division of Hematology Oncology Grand Rounds Schedule
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA